CAS No 284461-73-0 , 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-
methylpyridine-2-carboxamide

Title: Sorafenib
CAS Registry Number: 284461-73-0
CAS Name: 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
Synonyms: N-4-(Chloro-3-(trifluoromethyl)phenyl)-N￠-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
Manufacturers' Codes: Bay-43-9006
Molecular Formula: C21H16ClF3N4O3
Molecular Weight: 464.82
Percent Composition: C 54.26%, H 3.47%, Cl 7.63%, F 12.26%, N 12.05%, O 10.33%
Literature References: Multiple kinase inhibitor targeting both RAF kinase and receptor tyrosine kinases that promote angiogensis. Prepn: B. Riedl et al., WO 0041698 (2000 to Bayer); eidem, US 03139605 (2003); D. Bankston et al., Org. Process Res. Dev. 6, 777 (2002). Structure-activity study: U. R. Khire et al., Bioorg. Med. Chem. Lett. 14, 783 (2004). Characterization of kinase inhibition: S. M. Wilhelm et al., Cancer Res. 64, 7099 (2004). Mechanism of action study: D. J. Panka et al., Cancer Res. 66, 1611 (2006). LC determn in serum: S. Afify et al., J. Chromatogr. B 809, 99 (2004). Clinical pharmacokinetics: H. Richly et al., Int. J. Clin. Pharmacol. Ther. 41, 620 (2003). Analysis of clinical safety and efficacy: D. Strumberg et al., Eur. J. Cancer 42, 548 (2006). Clinical evaluation and brief review: H. DeGrendele, Clin. Colorectal Cancer 3, 16-18 (2003). Review of clinical development: B. I. Rini, Expert Opin. Pharmacother. 7, 453-461 (2006).
Properties: White solid, mp 205.6°.
Melting point: mp 205.6°
 
Derivative Type: Tosylate
CAS Registry Number: 475207-59-1
Trademarks: Nexavar (Bayer)
Molecular Formula: C21H16ClF3N4O3.C7H8O3S
Molecular Weight: 637.03
Percent Composition: C 52.79%, H 3.80%, Cl 5.57%, F 8.95%, N 8.80%, O 15.07%, S 5.03%
 
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Tyrosine Kinase Inhibitors.